Dianthus Therapeutics Presented New Trial Results
The company shared interim clinical data for its investigational autoimmune drug at the 2026 AANEM Annual Meeting.
Updated on Sept. 29, 2026 in Alzheimer’s
Live Poll
Do you believe clinical research on new therapies should be prioritized over existing treatment options?
Dianthus Therapeutics unveiled new clinical findings for its investigational monoclonal antibody, claseprubart, during the 2026 AANEM Annual Meeting in Orlando. The presentations highlighted interim results for patients with generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
Why it matters
This research aims to address significant unmet medical needs for consistent disease control and reduced treatment burdens in severe autoimmune conditions. The drug is engineered to selectively inhibit the active form of the C1s protein to improve patient outcomes.
An interim analysis of the CAPTIVATE Phase 3 trial for chronic inflammatory demyelinating polyneuropathy showed a 75% response rate among the first 40 participants. The company also presented one oral and four poster presentations at the meeting.
The players
Dianthus Therapeutics
This biotechnology company focuses on developing monoclonal antibodies to treat severe autoimmune diseases.
FDA
This federal agency is responsible for regulating the safety and efficacy of medical drugs in the United States.
The details
Claseprubart is a monoclonal antibody that uses YTE half-life extension technology to facilitate subcutaneous administration. The ongoing clinical programs target generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
Timeline
May 2026: The FDA granted Orphan Drug Designation to claseprubart.
September 29 to October 2, 2026: The AANEM Annual Meeting occurred in Orlando.
December 2026: Dianthus plans to report top-line data from the Phase 2 MoMeNtum trial.
2H 2028: The company plans to report top-line results from the Phase 3 EMERGE trial.
The Big Picture
This story tracks the progression of the CAPTIVATE Phase 3 trial to evaluate its potential impact on existing treatment standards for autoimmune disorders.
These clinical results represent early-stage development for a potential new subcutaneous treatment option for autoimmune patients. As an investigational agent, the drug is not yet available for prescription or clinical use.
The takeaway
Advancements in monoclonal antibody engineering like YTE half-life extension are aimed at reducing the administrative burden for patients with chronic conditions. Future clinical trial reports will clarify whether these therapies can effectively replace existing standard-of-care treatments.
What happens next
Dianthus Therapeutics is scheduled to report top-line data from its Phase 2 MoMeNtum trial in December 2026, followed by the release of Phase 3 EMERGE trial results in the second half of 2028.
Further reading
For more information on similar research developments, visit the Alzheimer’s section.
Live Poll
Do you believe clinical research on new therapies should be prioritized over existing treatment options?
